News

Xydalba is approved to treat ABSSSI with a two-dose regimen of 1000 mg followed one week later by 500 mg, each administered over 30 minutes. Actavis executive vice

Start-up procedures have already been started and patient enrolment is expected to be initiated in the second quarter of 2015. Both the parties will jointly conduct the trial

The new deal will allow Anabolic to expand its reach into new licensed healthcare practitioner segments and provide customers with added convenience and services. Emerson Ecologics president and

Under the deal, Blueprint will identify and optimize drug candidates using its kinase-focused drug discovery platform. The company will also conduct all research activities before filing an investigational

As part of the deal, GSK’s existing opiates business including related manufacturing sites in Latrobe (Tasmania) and Port Fairy (Victoria), and its portfolio of opiates products along with

The expansion will include emerging areas of research in the immune response to tumor neo-antigens, truly tumor-specific antigens generated as tumors accumulate genetic mutations. Additionally, new T cell

Lenvima is an orally administered molecular targeted agent that selectively inhibits the activities of an array of different molecules including VEGFR, FGFR, RET, KIT and PDGFR. VEGFR, FGFR

BL-8040, which is designed to treat acute myeloid leukemia, as well as other hematological indications, mobilizes cancer cells from the bone marrow and may therefore sensitize these cells

A total of 70 patients have been enrolled in the trial, which is examining the ability of AQX-1125 to reduce pain in female patients with BPS/IC, a chronic